Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-03-25 Remuneration Information
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
Remuneration Information Classification · 100% confidence The document is explicitly titled "Ultimovacs ASA - Remuneration Report 2023". It details the compensation structure, principles, and tables comparing management remuneration for 2023 and 2022, including base salary, benefits, variable remuneration, and share options costs. This content directly corresponds to the definition of a Remuneration Information report, which maps to the code DEF 14A (Proxy Solicitation & Information Statement often includes this, but the specific focus on remuneration makes DEF 14A the most precise fit among the options, as DEF 14A covers executive compensation disclosures). Reviewing the provided definitions: - DEF 14A: "Report detailing compensation for top executives and directors." - This document is a detailed report on executive compensation. Therefore, the classification is DEF 14A.
2024-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
Remuneration Information Classification · 98% confidence The document explicitly details 'Guidelines for remuneration to the executive management team' and states these guidelines 'have been prepared for approval by the Company's annual general meeting in 2024'. It covers fixed salary, bonus schemes, pension, share options, severance pay, and Board remuneration. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A filing type (Proxy Statement/Information Statement detailing executive compensation). Although it mentions approval at the AGM, the core subject is the remuneration structure itself, making DEF 14A the most specific fit over AGM-R or PSI.
2024-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
Annual Report Classification · 100% confidence The document is explicitly titled '2023 Annual Report' and contains standard sections for such a report, including a letter from the CEO, business overview, milestones, and references to financial statements and auditor's reports. It provides a comprehensive review of the company's activities for the fiscal year 2023, fitting the definition of a 10-K/Annual Report. FY 2023
2024-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
AGM Information Classification · 98% confidence The document text is titled "Innkalling til ordinær generalforsamling" (Notice of Annual General Meeting) in Norwegian and "Notice of Annual General Meeting" in English. It explicitly details the date (18. april 2024), time, location (virtual meeting), registration deadlines, and provides an agenda with voting items for the meeting, including election of the board and approval of accounts. This content is characteristic of the official notice sent to shareholders to convene the Annual General Meeting (AGM). While it contains elements that might be found in a Proxy Statement (DEF 14A) regarding voting instructions, the primary purpose and title identify it as the formal summons for the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-03-25 Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I ULTIMOVACS ASA" (Notice of Annual General Meeting in Ultimovacs ASA) and its English translation confirms this. The agenda items include approval of annual accounts, remuneration guidelines, election of the board, and authorizations related to share capital, which are standard topics for an AGM. This directly corresponds to the AGM Information category.
2024-03-25 Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting on April 18, 2024' for Ultimovacs ASA. This directly relates to the scheduling and calling of the AGM. According to the definitions, 'AGM Information (Code: AGM-R)' covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. While this is a notice *calling* the meeting, it is the primary document initiating the AGM process, making AGM-R the most appropriate classification over a general regulatory filing (RNS) or a proxy statement (PSI), as it sets the stage for the meeting itself.
2024-03-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.